Table 1.
Ongoing Clinical Trials of PD-1 Checkpoint Blockade in Hematologic Malignancies.
| Hematologic Disease | Phase | Disease Stage | PD-1/PD-L1 Inhibitor | Combination Therapy | Reference |
|---|---|---|---|---|---|
| Blood Cancer | Phase 1B | Relapsed/Refractory | Pembrolizumab | Single-agent | NCT01953692 |
| Multiple Myeloma | Phase 1 | Relapsed/Refractory | Pembrolizumab | Lenalidomide and dexamethasone | NCT02036502 |
| CLL and Indolent NHL | Phase 2 | Relapsed/Refractory | Pembrolizumab | Single-agent | NCT02332980 |
| Multiple Myeloma | Phase 2 | After HDT/ASCT | Pembrolizumab | Revlimid | NCT02331368 |
| Mycosis Fungoides or Sezary Syndrome | Phase 2 | Relapsed/Refractory | Pembrolizumab | Single-agent | NCT02243579 |
| Multiple Myeloma | Phase 1/2 | Relapsed/Refractory | Pembrolizumab | Pomalidomide and dexamethasone | NCT02289222 |
| HD, NHL, or Multiple Myeloma | Phase 1 | Relapsed/Refractory | Nivolumab | Ipilimumab or Lirilumab | NCT01592370 |
| NHL | Phase 1/2 | Relapsed/Refractory | Nivolumab | Urelumab | NCT02253992 |
| AML | Randomized Phase 2 | CR after chemotherapy | Nivolumab | Single-agent | NCT02275533 |
| CML | Phase 1B | Progressing after ≥2 TKIs | Nivolumab | Dasatinib | NCT02011945 |
| CLL, FL, DLBCL | Phase 1/2A | Relapsed/Refractory | Nivolumab | Ibrutinib | NCT02329847 |
| HD | Phase 2 | Relapsed/Refractory | Nivolumab | Single-agent | NCT02181738 |
| FL | Phase 2 | Relapsed/Refractory | Nivolumab | Single-agent | NCT02038946 |
| DLBCL | Phase 2 | Relapsed/Refractory | Nivolumab | Single-agent | NCT02038933 |
| Multiple Myeloma | Phase 1/2 | Relapsed/Refractory | Pidilizumab | Lenalidomide | NCT02077959 |
| DLBCL, FL | Phase 1B | Relapsed/Refractory | MPDL-3280A | Obinuzutumab | NCT02220842 |
| DLBCL, MCL | Phase 1B/2 | Relapsed/Refractory | MEDI-0680 | MEDI-551 (Anti-CD19 Antibody) | NCT02271945 |
Abbreviations: CLL, Chronic lymphomic leukemia; NHL, Non-Hodgkin's Lymphoma, AML, Acute myeloid Leukemia; CR, Complete remission; CML, Chronic myelogenous leukemia; HD, Hodgkin's lymphoma; TKI, Tyrosine kinase inhibitor; FL, Follicular lymphoma; DLBCL, Diffuse large B-cell lymphoma; MCL, Mantle cell lymphoma